Boston Scientific outperformed expectations in Q1 2026, driven by strong organic and acquisition-related growth, particularly in Cardiovascular and Urology segments. The integration of Axonics and Penumbra enhances its technology base while restructuring initiatives improve operational efficiency. The company’s diversified portfolio, global sales infrastructure, and innovation pipeline position it well amid evolving healthcare dynamics despite legal and regulatory risks. Key milestones ahead include regulatory approvals and ERP rollout phases that will influence execution momentum.